Pfizer Inc. (PFE) earnings on May 5, 2026
Prior outlook: Pessimistic Outcome: Partial
Pfizer shares reacted mildly despite missing earnings expectations. The stock managed a small gain, showing resilience amid negative sentiment.
PFE price around the earnings
26.45
Change: +0.6%
2026-05-05, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Partial
- Thesis published
Missed earnings, weak momentum, negative trend.
Pfizer missed its earnings expectations for the recent reporting period, and the stock continues to show weak price momentum and underperformance compared to the broader market. Despite some positive news, the overall trend is negative.
Context analyzed before publication
- Summary
- Mixed outlook, potential catalyst support.
- Reasoning
- Despite a positive catalyst from the FDA, the stock's overall momentum is weak, underperforming the broader market. While past earnings have been strong, the price continues to decline.
- Playbook
- The scenario is neutral with a positive FDA catalyst, but the overall momentum is weak. The technical picture is a key factor for a potential trend reversal.
- Trend
- Neutral evolution, catalyst support emerging.
Analysts
Drivers
-
Analysts
Positive
Analysts have set a price target about 10% above the current price. The average rating from analysts is a buy.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2.45
- Analysts covering the stock
- 27
- Average price target
- 29
- Lowest price target
- 24
- Highest price target
- 36
- Upside to price target
- 10.3%
- Revenue growth
- -1.2%
- Forward EPS
- 2.81
- Trailing EPS
- 1.36
- Analyst moves in the last 60 days
- 8
- Strong buy: 2
- Buy: 9
- Hold: 15
- Sell: 1
- Strong sell: 2
- Strong buy
- 2
- Buy
- 9
- Hold
- 15
- Sell
- 1
- Strong sell
- 2
- April 29, 2026 · Citigroup: Maintains rating (Neutral → Neutral)
- April 20, 2026 · RBC Capital: Reiterates rating (Underperform → Underperform)
- April 16, 2026 · CICC: Initiates coverage (Outperform)
- April 13, 2026 · UBS: Maintains rating (Neutral → Neutral)
- April 10, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)
- April 9, 2026 · B of A Securities: Maintains rating (Neutral → Neutral)
- March 24, 2026 · Guggenheim: Maintains rating (Buy → Buy)
- March 17, 2026 · HSBC: Maintains rating (Buy → Buy)
News and sentiment
Drivers
-
News & sentiment
Positive
The FDA has approved a new breast cancer therapy developed with Arvinas. This regulatory approval acts as a significant positive catalyst for the company.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (6)
- Pfizer, Pinterest And 3 Stocks To Watch Heading Into Tuesday — Benzinga
- Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy — Benzinga
- How To Earn $500 A Month From Pfizer Stock Ahead Of Q1 Earnings — Benzinga
- Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study — Benzinga
- Citigroup Maintains Neutral on Pfizer, Raises Price Target to $27 — Benzinga
- Pfizer Announces Topline Results From Phase 3 Magnetismm-5 Study Evaluating ELREXFIO As Monotherapy In Adults With RRMM; Primary Endpoint Met At Interim Analysis In Magnetismm-5 Trial — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock has underperformed the market over the last 30 days, showing a negative relative strength. This confirms the current weakness in price trend.
Evidence
- Average true range (ATR)
- 2%
- Distance to 52-week high
- -8.5%
- 14-day change (14d)
- -3.2%
- 30-day change
- -1.8%
- 30-day relative strength
- -12.5%
- Benchmark change
- +10.7%
- Nearest support
- 26.16
- Nearest resistance
- 28.74
- Volume accumulation ratio
- 0.94
Trends
Evidence
- Average earnings surprise
- +31.5%
- February 3, 2026: actual EPS 0.66 vs estimate 0.57 (surprise +16.2%)
- November 4, 2025: actual EPS 0.87 vs estimate 0.63 (surprise +37.4%)
- August 5, 2025: actual EPS 0.78 vs estimate 0.57 (surprise +35.9%)
- April 29, 2025: actual EPS 0.92 vs estimate 0.67 (surprise +36.5%)
Expected move
Drivers
-
Past earnings
Positive
The company has consistently beaten earnings expectations for its last several reports. The average surprise in earnings has been substantial, providing fundamental strength.
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 2.1%
- 75th percentile move
- 3.2%
- 90th percentile move
- 4.3%
- Up / down moves
- 9 / 10
- Average up move
- +3.4%
- Average down move
- -1.6%
Monitoring and close
What Pfizer Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Partial
- Consolidated
- +0.5%
- Max favorable move (MFE)
- 1.1%
- Max adverse move (MAE)
- 1.7%